Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes.

ABSTRACT:

Aims/hypothesis

Metformin is the most-prescribed oral medication to lower blood glucose worldwide. Yet previous systematic reviews have raised doubts about its effectiveness in reducing risk of cardiovascular disease, the most costly complication of type 2 diabetes. We aimed to systematically identify and pool randomised trials reporting cardiovascular outcomes in which the effect of metformin was 'isolated' through comparison to diet, lifestyle or placebo.

Methods

We performed an electronic literature search of MEDLINE, EMBASE and the Cochrane Library. We also manually screened the reference lists of previous meta-analyses of trials of metformin identified through a MEDLINE search. We included randomised controlled trials of adults with type 2 diabetes comparing any dose an

SUBMITTER: Griffin SJ 

PROVIDER: S-EPMC5552849 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature